LONDON: Nestle, the world’s biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros (US$111mil) to develop and market an experimental milk allergy test for infants.
The Swiss group would pay DBV Technologies 10 million euros upfront for rights to its skin patch test for cow’s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said yesterday.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!